For how we live.
BeiGene's PD-1 antibody, added to the HER2 drug zanidatamab and chemotherapy, lifted median overall survival to 26.4 months from 19.2 in the HERIZON-GEA-01 trial. The gain concentrated in the strongest HER2-expressers.
H. pylori infection and NSAIDs are the two most common causes of peptic ulcers. Treatment now turns on antibiotic resistance, which is quietly reshaping the first-line regimens.
Adding the immunotherapy to perioperative chemotherapy improved overall survival in resectable gastric and junction cancer — crossing the significance line the interim analysis had missed.
In 555,904 matched adults, screening endoscopy cut gastric cancer mortality in the 50s and 60s. Past 80, or with heavy comorbidity, the association reversed.
In the phase 3 DRAGON-01 trial, delivering paclitaxel directly into the abdominal cavity on top of standard chemotherapy raised median survival to 19.4 months from 13.9 in gastric cancer with peritoneal spread.
An Israeli case-control study found an apparent fourfold risk that vanished once the year before diagnosis was excluded. A Nordic study of 17,232 cancers found no association at all.